BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis.
Samuel S, Beljanski V, Van Grevenynghe J, Richards S, Ben Yebdri F, He Z, Nichols C, Belgnaoui SM, Steel C, Goulet ML, Shamy A, Brown D, Abesada G, Haddad EK, Hiscott J.
Samuel S, et al. Among authors: van grevenynghe j.
Mol Ther. 2013 Jul;21(7):1413-23. doi: 10.1038/mt.2013.91. Epub 2013 May 21.
Mol Ther. 2013.
PMID: 23689597
Free PMC article.